PDCD1 and neoplasm: As shown in Fig. 2H, AccuTOX® combined to anti-PD-1 was superior at impairing tumor growth with a survival rate of 90% compared to 40% with the use of the Accum® anti-PD-1 combination (Fig. 2I).